-+ 0.00%
-+ 0.00%
-+ 0.00%

IceCure Medical Receives Registration, Approval For Its ProSense System For Distribution By Swissmedic

Benzinga·11/18/2025 13:45:41
Listen to the news

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the ProSense® system and cryoprobes for the treatment of malignant or benign tissue of the breast, lung, liver, kidney, and musculoskeletal (bone), including palliative interventions, has been officially registered and approved for distribution by Swissmedic, the Swiss Agency for Therapeutic Products. These indications are the same as those for which ProSense® is approved in the European Union.